



For Health Professionals Who Care For Cancer Patients

Inside This Issue:

- **Editor's Choice** – New Programs: Idelalisib and Rituximab for Chronic Lymphocytic Leukemia, Temozolomide and Etoposide for Brain Tumours
 - **Benefit Drug List** – New: CNTMZETO, ULYIDELAR Deleted: CNIME, CNTAMCAR
 - **Cancer Drug Manual** – New: Idelalisib Revised: Abiraterone, Methotrexate, Nivolumab, Pomalidomide; TALLman lettering
 - **List of New and Revised Protocols, Provincial Pre-Printed Orders and Patient Handouts**: New: CNTMZETO, ULYIDELAR Revised: CNAJZRT, GICART, GIFUART, UGIGAVRAMT, GIRCRT, GIRINFRT, UGUPABI, UGUPAZO, UGUTEM, HNAVM, LUVERL, ULUAVNIV, LULACATRT, LULAPE2RT, LULAPERT, LUOTPERT, LUSCPERT, ULYFIBRU, ULYIBRU, UMPOMDEX
 - **Website Resources and Contact Information**
- TALLman lettering formatted: GICIRB, GICOXB, GIFFOXB, UGIGAVRAMT, UGUAXIT, GUEVER, UGUPAZO, LULAPE2RT, LULAPERT, LUOTPERT, LUSCPERT, ULKCMLP, ULYROMI, USATEMBEV; Capecitabine protocol handouts: GIAJCAP, GIAJCAPOX, GIAVCAP, GIAVTZCAP, GICAPIRI, GICAPOX, GICART, GICIRB, GICOXB, GICPART, GIGAJCC, GIGAJCPRT, GIGAVCC, GIGAVCCT, GIGAVECC, GIGAVEOCAP, GIGECC, GIPAJGAP, GIRAJCOX, GIRCAP, GIRCRT, GIRINFRT

EDITOR'S CHOICE

NEW PROGRAMS

Effective 1 August 2017, the BCCA Provincial Systemic Therapy Program has approved the following programs.

Lymphoma:

Idelalisib and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (ULYIDELAR) – The BCCA Lymphoma Tumour Group is launching this new treatment program as another option for patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL), who would currently be treated with ibrutinib (ULYIBRU). When compared to rituximab alone in a phase III trial, the combination of idelalisib and rituximab was associated with significant improvement in overall survival (92% vs. 80% at 12 months), progression-free survival (median not reached vs. 5.5 mos, HR 0.18), and quality of life. Patients receiving idelalisib experienced higher rates of fever, fatigue, nausea, chills and diarrhea. Please note that BCCA will only fund either idelalisib with rituximab, or ibrutinib, in the relapsed or refractory setting. Idelalisib with rituximab is not funded as a sequential treatment option for patients who have progressed on ibrutinib, except as a bridge to allogeneic transplant in patients who have received first-line ibrutinib for 17p deletion (ULYFIBRU) or high risk disease.

More details on the pharmacology of idelalisib can be found in the Cancer Drug Manual section [below](#).

EDITOR'S CHOICE

References:

Furman RR, Sharman JP, Coutre SE, et al: Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 2014;370:997-1007.

Neuro-Oncology:

Temozolomide and Etoposide for Recurrent Malignant Brain Tumours (CNTMZETO) – The BCCA Neuro-Oncology Tumour Group has introduced this oral regimen to replace the inpatient protocol CNIME. This new regimen has been shown to be active in patients with recurrent embryonal tumours (e.g., medulloblastoma) and gliomas not previously treated with temozolomide.¹⁻²

References:

1. Korones NK, et al. Temozolomide and oral vp-16 for children and young adults with recurrent or treatment-induced malignant gliomas. *Pediatr Blood Cancer* 2006;47:37-41.
2. Korones NK, et al. Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma. *Cancer* 2003;97(8):1963-8.

BENEFIT DRUG LIST

NEW PROGRAMS

Effective 1 August 2017, the following treatment programs have been added to the BCCA [Benefit Drug List](#):

Protocol Title	Protocol Code	Benefit Status
Therapy for recurrent malignant brain tumours using temozolomide and etoposide	CNTMZETO	Class I
Treatment of relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma using idelalisib and rituximab	ULYIDELAR	Restricted

DELETED PROGRAMS

Effective 1 August 2017, the following BCCA treatment programs have been deleted from the BCCA [Benefit Drug List](#):

Protocol Title	Protocol Code
Ifosfamide, mesna and etoposide in the treatment of recurrent brain tumours	CNIME
Second and Third line treatment of recurrent gliomas with carboplatin and high dose tamoxifen	CNTAMCAR

CANCER DRUG MANUAL

NEW MONOGRAPHS AND PATIENT HANDOUTS

Idelalisib Monograph and **Patient Handout** have been developed with expert review provided by Dr. Alina Gerrie (medical oncologist) and Linda Hamata (pharmacist) of the BCCA Lymphoma Tumour Group. Idelalisib is a selective inhibitor of PI3K δ kinase, which is active in the signalling pathways of B-cell malignancies. Idelalisib is taken orally twice daily, with or without food, following BCCA Protocol ULYIDELA. Serious side effects reported with idelalisib include diarrhea/colitis, pneumonitis, and ALT/AST elevations. Idelalisib should be avoided in patients with hepatitis, liver disease, or inflammatory bowel disease.

REVISED MONOGRAPHS AND PATIENT HANDOUTS

Abiraterone Monograph

- *Supply and Storage*: added head and neck cancer as a new Health Canada approved indication

Methotrexate Monograph

- *Cautions*: updated bullets which accompany Bleyer nomogram to clarify methotrexate levels

Nivolumab Monograph

- *Uses*: added head and neck cancer as a new Health Canada approved indication

Pomalidomide

- Monograph: updated information related to hepatic and renal toxicity in *Cautions, Side Effects, Dosage Guidelines*
- Handout: “See Your Doctor” section: added bullet for liver problems

TALLman lettering updated

The following drug names have been formatted throughout the Cancer Drug Manual:

- oBINutuzumab, PAZOPanib, PONATinib, romiDEPsin

LIST OF NEW AND REVISED PROTOCOLS, PRE-PRINTED ORDERS AND PATIENT HANDOUTS

BC Cancer Agency Protocol Summaries, Provincial Pre-Printed Orders (PPPOs) and Patient Handouts are revised periodically. New, revised or deleted protocols, PPPOs and patient handouts for this month are listed below. Protocol codes for treatment requiring BCCA Compassionate Access Program approval are prefixed with the letter “U”.

NEW PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED)

CODE	Protocol	PPPO	Patient Handout	Protocol Title
CNTMZETO	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Therapy for recurrent malignant brain tumours using temozolomide and etoposide

NEW PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED)

CODE	Protocol	PPPO	Patient Handout	Protocol Title
ULYIDELAR	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Treatment of relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma using idelalisib and rituximab

REVISED PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED)

CODE	Protocol	PPPO	Patient Handout	Changes	Protocol Title
CNAJZRT	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Concurrent therapy duration clarified</i>	Concomitant (dual modality) and adjuvant temozolomide for newly diagnosed malignant gliomas with radiation
GICART	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<i>Extravasation management clarified</i>	Curative combined modality therapy for carcinoma of the anal canal using mitomycin, capecitabine and radiation therapy
GIFUART	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<i>Extravasation management clarified</i>	Curative combined modality therapy for carcinoma of the anal canal using mitomycin, infusional fluorouracil and radiation therapy
UGIGAVRAMT	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Ramucirumab dilution clarified</i>	Second-line therapy for metastatic or locally advanced gastric or gastroesophageal junction cancer using weekly paclitaxel and ramucirumab
GIRCRT	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Timing of concurrent treatment clarified</i>	Combined modality adjuvant therapy for high risk rectal carcinoma using capecitabine and radiation therapy
GIRINFRT	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Timing of concurrent treatment clarified</i>	Combined modality adjuvant therapy for high risk rectal carcinoma using capecitabine, infusional fluorouracil and radiation therapy
UGUPABI	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Corticosteroid options updated</i>	Therapy for metastatic castration resistant prostate cancer using abiraterone and prednisone
UGUPAZO	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Minor typo corrected</i>	Palliative therapy for renal cell carcinoma using pazopanib
UGUTEM	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Minor typo corrected</i>	Therapy for Advanced Renal Cancer Using Temsirolimus
HNAVM	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Creatinine scheduling updated</i>	Treatment of head and neck cancer using methotrexate as standard therapy
LUAVERL	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Minor typo corrected</i>	Second- or third-line treatment of advanced non-small cell lung cancer with erlotinib
ULUAVNIV	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Eligibility clarified</i>	Treatment of advanced non-small cell lung cancer using nivolumab
LULACATRT	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Paclitaxel dilution clarified</i>	Treatment of locally advanced non-small cell lung cancer using carboplatin and paclitaxel with radiation therapy
LULAPE2RT	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Contact physician updated</i>	Treatment of locally advanced non-small cell lung cancer using alternative dosing of cisplatin and etoposide with radiation therapy
LULAPERT	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Contact physician updated</i>	Treatment of locally advanced non-small cell lung cancer using cisplatin and etoposide with radiation therapy
LUOTPERT	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Contact physician updated</i>	Treatment of thymoma using cisplatin and etoposide with radiation therapy
LUSCPERT	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Contact physician updated</i>	Treatment of limited stage small cell lung cancer using cisplatin and etoposide with radiation therapy

REVISED PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED)					
CODE	Protocol	PPPO	Patient Handout	Changes	Protocol Title
ULYFIBRU	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Eligibility clarified	Treatment of previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma with chromosome 17 p deletion using ibrutinib
ULYIBRU	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Eligibility clarified	Treatment of relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma using ibrutinib
UMYPOMDEX	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Renal and hepatic dosing updated</i>	Therapy of multiple myeloma using pomalidomide with dexamethasone

The following documents have been revised for TALLman lettering:

CODE	Protocol	PPPO	Protocol Title
GICIRB	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Palliative combination chemotherapy for metastatic colorectal cancer using irinotecan, bevacizumab and capecitabine
GICOXB	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Palliative combination chemotherapy for metastatic colorectal cancer using oxaliplatin, bevacizumab and capecitabine
GIFFOX B	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Palliative combination chemotherapy for metastatic colorectal cancer using oxaliplatin, fluorouracil, leucovorin, and bevacizumab
UGIGAVRAMT	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Second-line therapy for metastatic or locally advanced gastric or gastroesophageal junction cancer using weekly paclitaxel and ramucirumab
UGUAXIT	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Therapy for metastatic renal cell carcinoma using axitinib
GUEVER	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Therapy for advanced renal cancer using everolimus
UGUPAZO	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Palliative therapy for renal cell carcinoma using pazopanib
LULAPE2RT	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Treatment of locally advanced non-small cell lung cancer using alternative dosing of cisplatin and etoposide with radiation therapy
LULAPERT	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Treatment of locally advanced non-small cell lung cancer using cisplatin and etoposide with radiation therapy
LUOTPERT	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Treatment of thymoma using cisplatin and etoposide with radiation therapy
LUSCPERT	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Treatment of limited stage small cell lung cancer using cisplatin and etoposide with radiation therapy
ULKCMLP	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Treatment of chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia using ponatinib
ULYROMI	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Treatment of relapsed or refractory peripheral T-cell lymphoma with romidepsin
USATEMBEV	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Therapy for advanced solitary fibrous tumours and hemangiopericytoma using temozolomide and bevacizumab

The patient handouts for the following capecitabine protocols have been revised for instructions when a dose has been missed:

CODE	Protocol Title
GIAJCAP	Adjuvant therapy of colon cancer using capecitabine
GIAJCAPOX	Adjuvant combination chemotherapy for stage iii and iib colon cancer using capecitabine and oxaliplatin
GIAVCAP	Palliative chemotherapy for advanced colorectal cancer using capecitabine
GIAVTZCAP	Palliative therapy of metastatic neuroendocrine cancer of the pancreas, using temozolomide and capecitabine
GICAPIRI	First line palliative combination chemotherapy for metastatic cancer of the colon or rectum using irinotecan and capecitabine in patients not suitable for GIFOLFIRI
GICAPOX	Palliative chemotherapy for metastatic colorectal cancer using capecitabine and oxaliplatin
GICART	Curative therapy for cancer of the anal canal using combined mitomycin, capecitabine and radiation therapy
GICIRB	Palliative combination chemotherapy for metastatic colorectal cancer using irinotecan, bevacizumab and capecitabine
GICOXB	Palliative combination chemotherapy for metastatic cancer of the colon or rectum using oxaliplatin, bevacizumab and capecitabine
GICPART	Curative-intent combined modality therapy for cancer of the anal canal, using cisplatin, capecitabine and radiation therapy.
GIGAJCC	Adjuvant chemotherapy treatment of stomach cancer patients with D2 resection (node negative), or for those ineligible for adjuvant chemoradiation, using cisplatin and capecitabine
GIGAJCPRT	Adjuvant chemotherapy of gastric cancer patients with completely resected gastric cancer using cisplatin, capecitabine and radiation therapy
GIGAVCC	Palliative therapy for metastatic or locally advanced gastric, gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, or anal squamous cell carcinoma using cisplatin and capecitabine
GIGAVCCT	Palliative treatment of metastatic or locally advanced gastric, gastroesophageal junction or esophageal adenocarcinoma using cisplatin, capecitabine and trastuzumab (HERCEPTIN)
GIGAVECC	Palliative therapy for metastatic or locally advanced stomach or esophageal cancer using epirubicin, cisplatin and capecitabine
GIGAVEOCAP	Palliative therapy for metastatic or locally advanced gastric or esophagogastric cancer using epirubicin, oxaliplatin and capecitabine
GIGECC	Treatment of operable cancer of the stomach, stomach-esophagus junction or lower 1/3 esophagus, given before and after surgery, using epirubicin, cisplatin and capecitabine
GIPAJGCAP	Adjuvant chemotherapy for pancreatic adenocarcinoma using gemcitabine and capecitabine
GIRAJCOX	Adjuvant combination chemotherapy for stage iii rectal cancer using capecitabine and oxaliplatin.
GIRCAP	Adjuvant therapy for stage ii and iii rectal cancer using capecitabine, for patients previously treated with radiation therapy and surgery,
GIRCRT	Adjuvant therapy for high risk cancer of the rectum with combined capecitabine and radiation therapy
GIRINFRT	Adjuvant therapy for high risk cancer of the rectum using capecitabine, infusional fluorouracil and radiation therapy

WEBSITE RESOURCES AND CONTACT INFORMATION

WEBSITE RESOURCES	WWW.BCCANCER.BC.CA
Systemic Therapy Update	www.bccancer.bc.ca/health-professionals/professional-resources/systemic-therapy/systemic-therapy-update
Reimbursement & Forms: Benefit Drug List, Compassionate Access Program	www.bccancer.bc.ca/health-professionals/professional-resources/systemic-therapy
Cancer Drug Manual	www.bccancer.bc.ca/health-professionals/professional-resources/cancer-drug-manual
Cancer Management Guidelines	www.bccancer.bc.ca/health-professionals/professional-resources/cancer-management-guidelines
Cancer Chemotherapy Protocols, Pre-Printed Orders, Protocol Patient Handouts	www.bccancer.bc.ca/health-professionals/professional-resources/chemotherapy-protocols
Systemic Therapy Program Policies	www.bccancer.bc.ca/health-professionals/professional-resources/systemic-therapy
CON Pharmacy Educators	www.bccancer.bc.ca/health-professionals/professional-resources/pharmacy

CONTACT INFORMATION	PHONE	FAX	EMAIL
Systemic Therapy Update Editor			bulletin@bccancer.bc.ca
Provincial Systemic Therapy Program	604-877-6000 x 672247		mclin@bccancer.bc.ca
To update contact information of any CON sites, please contact:			bulletin@bccancer.bc.ca
Oncology Drug Information	604-877-6275		druginfo@bccancer.bc.ca
Education Resource Nurse	604-877-6000 x 672638		nursinged@bccancer.bc.ca
Library/Cancer Information	604-675-8003 Toll Free 888-675-8001 x 8003		requests@bccancer.bc.ca
Pharmacy Professional Practice	604-877-6000 x 672247		mclin@bccancer.bc.ca
Nursing Professional Practice	604-877-6000 x 672623		ilundie@bccancer.bc.ca
OSCAR	888-355-0355	604-708-2051	oscar@bccancer.bc.ca
Compassionate Access Program (CAP)	604-877-6277	604-708-2026	cap_bcca@bccancer.bc.ca
Pharmacy Chemotherapy Certification	250-712-3900 x 686741		rxchemocert@bccancer.bc.ca
BCCA-Abbotsford Centre	604-851-4710 Toll Free 877-547-3777		
BCCA-Centre for the North	250-645-7300 Toll Free 888-775-7300		
BCCA-Fraser Valley Centre	604-930-2098 Toll Free 800-523-2885		
BCCA-Sindi Ahluwalia Hawkins Centre for the Southern Interior	250-712-3900 Toll Free 888-563-7773		
BCCA-Vancouver Centre	604-877-6000 Toll Free 800-663-3333		
BCCA-Vancouver Island Centre	250-519-5500 Toll Free 800-670-3322		

EDITORIAL REVIEW BOARD

Mario de Lemos, PharmD, MSc (Oncol) (Acting Editor)
 James Conklin, BSc(Pharm), ACPR
 Rob Crisp, BScPT, MBA
 Jagbir Kaur, RN, MN

Lorraine Leitz, MLS
 Caroline Lohrisch, MD
 Alison Pow, BSc(Pharm)